In a report released today, Keith Devas from Jefferies reiterated a Buy rating on Kenvue, Inc. (KVUE – Research Report), with a price target of $27.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Keith Devas’s rating is based on a combination of factors that suggest a positive outlook for Kenvue, Inc. Despite recent concerns about destocking and cautious consumer behavior, these issues were anticipated, and the company’s guidance remains unchanged. This stability, coupled with a recent 6% decline in share price, presents an opportunity for investors as the company embarks on a self-help transformation.
Furthermore, Kenvue’s skincare segment, particularly Neutrogena, is showing signs of recovery, driven by effective promotional strategies. The company’s reinvestment in marketing and R&D is expected to bolster growth, aligning with industry peers. Additionally, the valuation analysis indicates a potential 20% upside, with shares likely to re-rate closer to industry averages as Kenvue’s growth transformation progresses.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $29.00 price target.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KVUE in relation to earlier this year.